Patient Age/Gender: 13 months Female Printed: 14-Mar-19 09:30:34

				Reported/
Procedure	Result	Units	Ref Interval	Accession Collected Received Verified
CD45+ Cell Proliferation by anti-CD3	10.1 L	00	[>=10.2]	19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19
-				10:00:00 14:09:00 17:44:59
CD3+ Cell Proliferation by anti-CD3	13.4 L	olo	[>=13.5]	19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19
			r	10:00:00 14:09:00 17:44:59 19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19
CD45+ Cell Prolif by anti-CD3/CD28	28.9 L	00	[>=29.0]	10:00:00 14:09:00 17:44:59
CD3+ Cell Prolif by anti-CD3/CD28	24.2 L	8	[>=24.3]	19-057-114246 26-Feb-19 26-Feb-19 10:00:00 14:09:00 17:44:59
CDS+ CEII PIOIII by anti-CDS/CD20	24.2 1	6	[>=24.5]	
CD45+ Cell Prolif by anti-CD3 and IL-2	33.0 L	8	% [>=33.1]	19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19 10:00:00 14:09:00 17:44:59
ebis: cell lioill by anel ebs and il 2		0		
CD3+ Cell Prolif by anti-CD3 and IL-2	36.0 L	00	[>=36.1]	19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19
• · · · · · · · ·				10:00:00 14:09:00 17:44:59
Lymphocyte Proliferation-AntiCD3, Interp	See Note			19-057-114246 26-Feb-19 26-Feb-19 26-Feb-19
				10:00:00 14:09:00 17:44:59

26-Feb-19 10:00:00 Lymphocyte Proliferation-AntiCD3, Interp: INTERPRETIVE INFORMATION: Lymphocyte Proliferation, Anti-CD3,Flow

This test measures T lymphocyte proliferation in response to stimulation with anti-CD3, anti-CD3/anti-CD28, and anti-CD3/Interleukin-2, determined by flow cytometry. Proliferating cells are detected by fluorescent labeling. Results are reported as percent proliferating cells of the total specific cell populations. This is a second-level test to be performed after Lymphocyte Proliferation to Mitogens (PHA, Con A, and PWM) by Flow Cytometry has been assessed.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

\* Abnormal, # = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, @ = Reference Lab